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concentrated on optimizing dose schedules, we proposed a 
study demonstrating that using more technically advanced 
techniques would result in equivalent symptomatic relief and 
reduce symptomatic oesophagitis. 
 
Material and Methods: Thirty-five patients with symptomatic 
locally advanced or metastatic NSCLC were treated using a 
three-dimensional conformal technique and standardized 
dose regimens of 39Gy in 13 fractions, 20Gy in 5 fractions or 
17Gy in 2 fractions. Treatment plans sought to minimize 
oesophageal dose and oesophagitis was recorded during and 
at one month and three months following radiation therapy 
where applicable. Mean dose to the irradiated oesophagus 
was calculated for all treatment plans. 
 
Results: At follow-up of one month after therapy for all 
patients accrued, there were no grade three or higher 
oesophageal symptoms of oesophagitis or dysphagia reported. 
Four patients (11.4%) had experienced grade 2 toxicity. All 
patients in the study derived clinical benefit from the 
radiation therapy course. 
 
Conclusion: Use of three-dimensional conformal radiation 
techniques is widely practiced for treating intra-thoracic 
symptoms in the setting of NSCLC, however no direct study 
exists proving its superiority in reducing toxicity. This trial is 
the first of its kind showing that such techniques do provide 
patients with lower rates of oesophageal toxicity whilst 
yielding acceptable rates of symptom control. (Sponsored by 
the All-Ireland Cooperative Oncology Research Group 
(ICORG). Trial registration number 06-34) 
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Purpose or Objective: Although there is no standard 
treatment for postoperative recurrence of non-small-cell lung 
cancer (NSCLC), radiotherapy is occasionally used in the 
treatment of loco-regional recurrences. The objective of this 
study is to analyze clinical results of curative intent 
radiotherapy for loco-regional recurrence of NSCLC after 
complete surgical resection. 
 
Material and Methods: A total of 38 patients, who had 
developed loco-regional recurrence after complete resection 
and received curative intent radiotherapy between 1999 and 
2014, were retrospectively analyzed. There were 29 male 
patients and 9 female patients. The age range was 47-89 
years (median 70 years). 25 patients had adenocarcinoma, 
thirteen patients squamous cell carcinoma. There were 29 
patients with regional lymph nodes recurrence, and 10 
patients with local recurrence at primary or anastomotic sites 
with or without lymph nodes recurrence. No patient had 
distant metastasis at presentation. The clinical endpoints 
included overall survival, progression-free survival, loco-
regional recurrence within the irradiated field, and any other 
recurrence. The overall survival and local control rate were 
calculated from the day of radiotherapy completion and 
estimated by Kaplan-Meier method. 
 
Results: The median total dose of radiotherapy was 60 Gy 
(range, 50–70 Gy). Thirteen of the 38 patients were treated 
with concurrent chemotherapy. The median follow-up time 
after radiotherapy was 30.4 (2.9–151) months. 1–5-year 
survival rates were 81.2, 69.6, 55.7, 48.5 and 39.6%, 
respectively. The 5-year progression-free survival, and local 
control rate were 32.6%, and 67.6%, respectively. Eight 
patients have survived more than 5 years. There was no 
significant difference between patients with lymph nodes 
recurrence and those with local recurrence in overall 
survival. 
 
Conclusion: Radiation therapy for loco-regional recurrence 
after complete resection provides acceptable disease 
control. Curative intent radiation therapy can be the 
treatment of choice if no evidence of metastasis is observed. 
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Purpose or Objective: To determine predictive factors of 
local recurrence (LR) after Stereotactic Body Radiotherapy 
(SBRT). 
 
Material and Methods: Data were retrospectively analyzed 
from 136 consecutive patients and 156 lung tumors treated 
with curative intent SBRT between April 2012 and December 
2014 at our institution. Most patients had early lung cancer 
(76%). SBRT was also included in the treatment strategy for 
locally advanced (3%) or oligometastatic (21%) patients with 
an intent to complete response. 
 
Results: The median follow-up was 21.8 months (2.4-70.8 
months). The median age at diagnosis was 66,5 years (33-89 
years) and median performance status was 0,5 (range 1-3). 
54% patients had a smoking history with a median VEMS of 
62,2%. Histological confirmation was obtained in 67%: 35% 
adenocarcinoma, 21% squamous cell carcinoma, 5% 
undifferenciated NSCLC and 5% other. Molecular markers 
were known in 27 tumors (17%): negative markers in 10%, 
KRAS mutation in 6%, other in 2%. Tumor location was central 
in 28%, peripheral in 48%, and intermediate in 24%. Median 
SUVmax at diagnosis was 7,1. Median ITV was 31,7 cc (0,56-
104,8 cc) and median Biological effective dose (BED) was 
123,8 Gy (72-151,2 Gy, α/β=10). 11 LR occurred resulting in a 
2 year LR rate of 8% [CI 95%: 3-14%]; median: not reached; 
mean time to LR: 38.4 month [CI 95%: 36-39.6]. BED ≤100Gy 
(HR=5 [CI 95%: 1.1-22]; p=0.03), and Internal Target Volume 
(ITV) ≥20cc (HR=4.9 [CI 95%: 1.3 -18.5); p=0.02) were 
associated with a decreased LR in the multivariate analysis 
(MVA). Histology (squamous cell carcinoma), central location, 
and SUVmax of the treated lesion > 8 were not associated 
with local control in the MVA. Delay from diagnosis to SABR 
and molecular markers were not correlated with LR results in 
the univariate analysis. Two years overall survival and 
progression free survival rates were respectively 74% (IC 95%: 
65-83%) and 62% (IC 95%: 52-72%). 
 
Conclusion: BED should carefully be taken into account, 
particularly in case of tumors that exceed 20 cc 
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Purpose or Objective: It is unknown whether dose-response 
for the primary tumor is different from that of the involved 
lymph nodes (LN). As the recurrence rate is much lower in 
LN, we hypothesized that involved LN need a lower radiation 
dose than the primary tumor. 
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Material and Methods: A retrospective analysis of 
prospective data was performed on patients with locally 
advanced NSCLC treated with radiotherapy. Three dose 
groups were defined based on EQD2,T (A: < 50 Gy, B: 50-55 
Gy, C: > 55 Gy). The primary endpoint was involved nodal 
relapse (INR). An actuarial Kaplan-Meier analysis was 
performed to evaluate the cumulative proportion of INR and 
primary tumor progression per dose group. 
 
Results: From 2006 to 2010, 75 consecutive patients were 
included in this study. Groups A, B and C consisted of 22, 24 
and 29 patients respectively. Median follow-up was 7 months. 
All patient characteristics were well balanced between the 3 
dose groups. A total of 142 lymph nodes were included in the 
analysis (A: 49; B: 36; C: 57). Any relapse 
(locoregional/distant) occurred in 58 patients (77%). INR was 
observed in 18% in group A, 8% in group B and 14% in group C. 
No dose-response relationship was observed in the involved 
LN (p=0.35). Primary tumor progression was seen in 55%, 42% 
and 28% in group A, B and C respectively. A significant dose-
response relationship was observed in the primary tumor 
(p=0.02). Baseline nodal diameter was not associated with 
INR (HR 1; p=0.82). 
 
 
Conclusion: 
The results of this study suggest that LN control can be 
achieved at lower radiation dose than needed for the primary 
tumor. Prospective dose de-escalation studies on LN are 
needed to decrease incidence of severe oesophagitis without 
compromising local control. 
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Purpose or Objective: The CC Chemokine Ligand 18 (CCL18) 
is produced by alveolar macrophages in patients with 
fibrosing lung disease and its concentration is increased in 
various inflammatory and fibrotic lung diseases. In this study 
we aimed to analyze the role of CCL18 as a potential 
prognostic biomarker for the development of radiation 
induced lung disease (RILD) after thoracic irradiation. 
 
Material and Methods: Between August 2011 and February 
2012, 60 patients were enrolled prospectively in the study. 
Forty-six patients were treated for lung cancer; thirteen had 
an esophageal cancer and one a thymoma. Patients were 
treated either with conventionally fractionated (n=47) or 
hypo-fractionated (n=13) radiotherapy, 9 patients were 
treated adjuvant, 3 neoadjuvant, 4 with palliative intent and 
44 with a definitive radiochemotherapy. The CCL18 levels in 
serum were quantified with ELISA (enzyme-linked 
immunosorbent assay) at predefined time points; before 
treatment, after 30 Gy, after 60 Gy (for conventional 
fractionation), at 6 weeks after completion of treatment and 
3 months after therapy. These results were then correlated 
with clinical signs of RILD routinely performed computed 
tomographies (CTs) at 6 weeks and 3 months after the last 
treatment. 
 
Results: Twenty three patients developed radiologic signs of 
RILD but only three of them developed symptoms. The mean 
CCL18 levels, for the whole group of patients, were before 
treatment 110 ng/ml (standard deviation, + 53) and at the 
end of treatment 85 ng/ml (+ 73). During the first (6 weeks 
after treatment) and second follow-up (3 months after 
treatment) the mean CCL18 levels were 93 ng/ml (+ 57) and 
104 ng/ml (+ 49), respectively. The CCL18 concentrations in 
serum were not significantly elevated in the group of patients 
who developed a RILD. The mean CCL18 levels at six weeks 
and three months after treatment were in the RILD-group 94 
ng/ml (+ 62) and 104 ng/ml (+ 61) and in the non-RILD-group 
93 ng/ml (+ 54) and 103 ng/ml (+ 39). Patients with elevated 
CCL18 over the mean had a slightly worse local control 
(p=0,047) and a slightly worse overall survival which didn’t 
reach statistical significance. 
 
Conclusion: These findings do not suggest that the 
chemokine CCL18 is involved in the development of RILD in 
patients undergoing radiotherapy for chest tumors. 
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Purpose or Objective: In the present study we have 
evaluated local control, overall survival (OS) and toxicity of 
re-irradiation with stereotactic body radiation therapy (SBRT) 
in patients with recurrent/progressive primary or secondary 
lung tumors after previous radical radiation therapy or SBRT. 
 
Material and Methods: Between August 2011 and December 
2014, 9 patients (6 men and 3 women) received a second 
course of SBRT in single (23 Gy or 30 Gy) or multiple fractions 
(15 Gy x 3). The median volume was 19.8 cc (range 3,7 - 46,8 
cc). The median interval from previous irradiation was 18 
months (range 12 - 47 months). Previous treatment included 
radical radiation therapy (60 Gy) in 33% of lesions and single-
fraction SBRT (23 Gy or 30 Gy) in 67% of lesions. 
 
Results: The median follow-up was 11 months (range 2 – 38 
months). The median OS after the second course of SBRT was 
12 months (range 3 – 39 months). The 6- and 12-months 
survival rates were 100% and 88%, respectively. No patient 
developed grade ≥ 2 t oxicity. Complete response was 
observed in 2 patients (22%) and stable disease in 6 patients 
(66%). One patient died for progressive systemic disease. 
 
Conclusion: Re-irradiation with SBRT for 
recurrent/progressive primary or secondary lung tumors is a 
feasible treatment associated with good local control and 
acceptable toxicity 
 
 
